Table 2.
Relationship between galectin 1 (Gal-1), integrin β1, and clinicopathologic features in 94 gastric cancer patients
| Groups | No. of cases | Cases positive for Gal-1, n (%) | P-value | Cases positive for integrin β1, n (%) | P-value |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 59 | 34 (57.6) | 0.438 | 27 (45.8) | 0.061 |
| Female | 35 | 23 (65.7) | 23 (65.7) | ||
| Tumor diameter | |||||
| <5 cm | 55 | 33 (60.0) | 0.880 | 25 (45.5) | 0.074 |
| ≥5 cm | 39 | 24 (61.5) | 25 (64.1) | ||
| Differentiation | |||||
| Well | 1 | 1 (100) | 0.099 | 1 (100.0) | 0.381 |
| Moderate | 27 | 12 (44.4) | 12 (44.4) | ||
| Poor | 66 | 44 (66.7) | 37 (56.1) | ||
| Histological classification | |||||
| Papillary adenocarcinoma | 5 | 2 (40.0) | 0.611 | 1 (20.0) | 0.300 |
| Tubular adenocarcinoma | 67 | 40 (59.7) | 36 (53.7) | ||
| Mucinous adenocarcinoma | 5 | 4 (80.0) | 4 (80.0) | ||
| Signet-ring cell carcinoma | 17 | 11 (64.7) | 9 (52.9) | ||
| Lymph node metastasis | |||||
| Yes | 64 | 49 (76.6) | 0.000 | 43 (67.2) | 0.000 |
| No | 30 | 8 (26.7) | 7 (23.3) | ||
| Distant metastasis | |||||
| Yes | 14 | 13 (92.9) | 0.007 | 12 (85.7) | 0.008 |
| No | 80 | 44 (55.0) | 38 (47.5) | ||
| TNM stage | |||||
| I + II | 40 | 14 (35.0) | 0.000 | 9 (22.5) | 0.000 |
| III + IV | 54 | 43 (79.6) | 41 (75.9) | ||